The research performed by Gulley et al. [92] found that 9 out of 16 patients diagnosed with recombinant CEA-MUC-1-TRICOM poxviral-based robust tumor vaccines had an increase in both CD8+ and CD4+ immune responses. This evidence concerns the gene CD8A and neoplasm.